Open Menu

Meetings & Education

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.

download

Background:

In the United States, non-squamous histology accounts for approximately 70% of all non-small-cell lung cancers (NSCLCs), and stage IV disease with no targetable alterations is associated with poor prognosis, with a median overall survival of around 2 years. Immunotherapy targeting programmed cell death (ligand)-1 (PD-1/PD-L1) with or without platinum-based chemotherapy (PBC) is a standard of care first-line (1L) chemotherapy for patients with advanced non-squamous NSCLC. Despite the efficacy of this approach, not all patients respond to PD-1/PD-L1 immunotherapy and more effective therapeutic strategies are needed. Inhibition of the co-inhibitory T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) pathway in combination with PD-1/PD-L1 blockade to increase immunotherapy efficacy is being investigated in NSCLC, as well as other cancer types. Preliminary results (Hiltermann TJN, et al. J Thorac Oncol [WCLC] 2024; abstract OA11.03) show that rilvegostomig, a monovalent, bispecific, humanized IgG1 monoclonal antibody targeting both PD-1 and TIGIT receptors, achieved encouraging antitumor response rates and durable responses with a manageable safety profile in NSCLC. The phase 3, randomized, double-blind, multicenter ARTEMIDE-Lung03 study (NCT06627647) will assess the efficacy and safety of rilvegostomig versus pembrolizumab, in combination with platinum-based doublet chemotherapy, as 1L treatment for participants (pts) with non-squamous metastatic NSCLC (mNSCLC).

Methods:

Approximately 878 pts will be randomized 1:1 to either Arm A: rilvegostomig + PBC (pemetrexed + cisplatin or carboplatin) intravenous (IV) every three weeks (Q3W) for 4 cycles followed by rilvegostomig + pemetrexed maintenance treatment IV Q3W, or Arm B: pembrolizumab + chemotherapy IV Q3W for 4 cycles followed by pembrolizumab + pemetrexed maintenance IV Q3W. Eligibility criteria include histologically or cytologically confirmed non-squamous mNSCLC not amenable to curative treatment, tumors expressing PD-L1 (TC ≥1%), an Eastern Cooperative Oncology Group performance status of 0 or 1, no sensitizing EGFR mutations, ALK or ROS1 rearrangements, or mutations in other oncogenes with approved 1L therapies available. Dual primary endpoints are progression-free survival (Response Evaluation Criteria in Solid Tumors v1.1 by blinded independent central review) and overall survival. Safety/tolerability and biomarkers will also be assessed. The study will be conducted across approximately 350 sites in 25−30 countries.

Disclaimer

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Author Details

Clarissa Mathias

Oncoclínicas&Co. and Hospital Santa Izabel, Salvador, Bahia, Brazil

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

View MoreAbstract Disclosure
open_in_new

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Manage Consent Preferences

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Cookie List

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel

checkbox labellabel

checkbox labellabel

• View Cookies

• Name

cookie name

Save Settings

Download